AbbVie Unveils Promising 148-Week VALUE Trial Data for Risankizumab at IFPA Conference

AbbVie recently presented promising real-world data from its VALUE trial at the IFPA Conference (also known as the World Psoriasis & Psoriatic Arthritis Conference), reporting that risankizumab achieved more significant, durable clinical responses versus other biologics in moderate to severe psoriasis.¹

Image Credit: © IIIRusya - stock.adobe.com

Background and Methods

The VALUE study (NCT03982394) is an ongoing, comprehensive, multi-country, prospective post-marketing observational study aimed at evaluating the real-world effectiveness and durability of risankizumab in treating moderate-to-severe psoriasis compared to other biologics.²

The study seeks to address the challenges of suboptimal psoriasis management, increased disease burden, treatment discontinuation, and satisfaction, by comparing the long-term outcomes of risankizumab with those of other biologics.

Patients aged 18 and older with moderate-to-severe psoriasis were enrolled and treated with either risankizumab or other biologics in a 2:1 ratio, based on the treating physician's discretion and local labeling. Key effectiveness endpoints included the Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), Treatment Satisfaction Questionnaire for Medication (TSQM) scores, and rates of treatment changes.

Findings

The interim analysis included 2,639 patients, with 1,765 receiving risankizumab and 874 receiving other biologics. Baseline demographics and characteristics were largely similar between the 2 groups, though notable differences included a higher baseline PASI score in the risankizumab group, a greater history of psoriatic arthritis, and a higher proportion of bio-experienced patients.

Following propensity score matching, the results revealed that a significantly higher proportion of patients in the risankizumab group achieved and maintained a PASI 90 response from week 16 up to week 148 compared to the cohort treated with other biologics. Additionally, fewer patients in the risankizumab group changed treatments during the study period.

At week 148, patients treated with risankizumab demonstrated significantly lower absolute PASI scores and higher rates of achieving PASI 90 and PASI 100. Furthermore, the DLQI scores were significantly better in the risankizumab group, indicating a better quality of life. Patients on risankizumab also reported higher TSQM global satisfaction scores.

Safety profiles for risankizumab remained consistent with previous studies.

Conclusions

"This updated analysis from the VALUE study demonstrates that patients treated with risankizumab achieve higher durable clinical responses in real-world practice compared to OtherBios," wrote Thaçi et al.

As the study is ongoing and not all patients have reached the 148-week mark, researchers noted that these promising findings suggest that risankizumab could offer a more reliable and satisfying treatment option for psoriasis patients.

Further updates from the VALUE study are anticipated to provide more comprehensive insights, with anticipated study completion being July 2025.²

References

1. Thaçi D, Ohtsuki M, Maul JT, et al. Real-world effectiveness of risankizumab in the multi-country post-marketing VALUE study: 148-week interim analysis. Presented at: World Psoriasis & Psoriatic Arthritis Conference; June 27-29, 2024; Stockholm, Sweden.
2. ClinicalTrials.gov. Real-world effectiveness of risankizumab in the multi-country post-marketing VALUE study: 148-week interim analysis. NCT03982394. https://clinicaltrials.gov/study/NCT03982394. Accessed June 28, 2024.